EUnetHTA Joint Action 3 (2016-20) JA3-WP4
2017 - PDF

This is the final project plan of the pharma JA on Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).